Scarica l'app Stockscreener
36.60
4.45%
1.56
Dopo l'orario di chiusura:
36.60
Precedente Chiudi:
$35.04
Aprire:
$34.86
Volume 24 ore:
817.28K
Relative Volume:
2.20
Capitalizzazione di mercato:
$1.84B
Reddito:
$345.60M
Utile/perdita netta:
$-79.01M
Rapporto P/E:
-22.81
EPS:
-1.6045
Flusso di cassa netto:
$-18.62M
1 W Prestazione:
+17.46%
1M Prestazione:
+20.12%
6M Prestazione:
+11.79%
1 anno Prestazione:
-21.64%
Intervallo 1D:
$34.35
$36.97
Intervallo di 1 settimana:
$31.14
$36.97
Portata 52W:
$23.15
$49.05
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Confronta IMCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
36.60 | 1.57B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Deutsche Bank | Buy |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales - Yahoo Finance
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline - Yahoo Finance
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance - Yahoo Finance
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):